DefiniGEN: Leading the Way in Drug Discovery

“We have used several of the services provided by UKTI Japan from the very start of our market entry strategy in Japan. They come highly recommended.”

Dr. Masashi Matsunaga – DefiniGEN, Business Development Manager

DefiniGEN is a biotech spinout company established by the University of Cambridge in April 2012.

The company’s specialty is to provide a wide range of human cell products from iPS (pluripotent stem) cells, including liver, pancreas, and lung cells, to the life science and drug discovery sectors.

The company set its sights on Japan early on as it is the biggest Asian market for drug discovery, and the number 3 market in the world after the US and Europe. It is also a country of innovation as well as being a hub of iPS discovery.

The remainder of this article is a resource for members only. Please register or login to access. 

Get free and unlimited access to in-depth market reports, videos, invitations to relevant events and priority support. Join here.